Product line

Dow intends not to compete in the established market segments
but to develop specialty areas which may be required for development.

Immunology
  • Freelite [Multiple Myeloma]

    (Reimbursed in 2009, first case in the world)

  • Hevylite [MM, MRD]
  • IgG Subclass [PID, SAD]
  • Chromogranin A [NETs]

    (New Technology Approved in 2015, Reimbursed in 2018)